Eton Pharmaceuticals, Inc.ETONEarnings & Financial Report
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative therapies for rare diseases, pediatric care and hospital care segments. It mainly operates in the U.S. market, partnering with medical stakeholders to deliver accessible high-quality treatments to underserved patients.
ETON Q4 FY2025 Key Financial Metrics
Revenue
$21.3M
Gross Profit
$13.1M
Operating Profit
$2.5M
Net Profit
$1.5M
Gross Margin
61.6%
Operating Margin
11.6%
Net Margin
7.0%
YoY Growth
82.7%
EPS
$0.06
Eton Pharmaceuticals, Inc. Q4 FY2025 Financial Summary
Eton Pharmaceuticals, Inc. reported revenue of $21.3M (up 82.7% YoY) for Q4 FY2025, with a net profit of $1.5M (up 348.0% YoY) (7.0% margin). Cost of goods sold was $8.2M, operating expenses totaled $10.6M.
Key Financial Metrics
| Total Revenue | $21.3M |
|---|---|
| Net Profit | $1.5M |
| Gross Margin | 61.6% |
| Operating Margin | 11.6% |
| Report Period | Q4 FY2025 |
Eton Pharmaceuticals, Inc. Annual Revenue by Year
Eton Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $80.0M).
Eton Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Eton Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $21.3M | +82.7% | $1.5M | 7.0% |
| Q3 FY2025 | $22.5M | +117.5% | $-1.9M | -8.6% |
| Q2 FY2025 | $18.9M | +108.6% | $-2.6M | -13.7% |
| Q1 FY2025 | $17.3M | +116.9% | $-1.6M | -9.1% |
| Q4 FY2024 | $11.6M | +59.3% | $-598.0K | -5.1% |
| Q3 FY2024 | $10.3M | +46.9% | $627.0K | 6.1% |
| Q2 FY2024 | $9.1M | -24.4% | $-3.0M | -33.5% |
| Q1 FY2024 | $8.0M | +50.2% | $-811.0K | -10.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0M | $9.1M | $10.3M | $11.6M | $17.3M | $18.9M | $22.5M | $21.3M |
| YoY Growth | 50.2% | -24.4% | 46.9% | 59.3% | 116.9% | 108.6% | 117.5% | 82.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $30.8M | $31.8M | $35.8M | $76.1M | $84.0M | $101.7M | $104.5M | $92.1M |
| Liabilities | $15.3M | $18.4M | $19.9M | $51.7M | $59.6M | $77.7M | $81.4M | $66.0M |
| Equity | $15.5M | $13.5M | $16.0M | $24.4M | $24.4M | $24.0M | $23.1M | $26.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.5M | $1.3M | $3.0M | $-765000 | $2.1M | $8.0M | $12.0M | $-11.6M |